CAR-T cell therapy in developing countries: how long should we wait?
Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence.However, the survival rates for patients with cancer in these regions are notably lower than Panel Mount Fuseholder those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments.Chimeric antigen receptor